Vol 54, No 5 (2020)
Research Paper
Published online: 2020-07-08

open access

Page views 2987
Article views/downloads 1088
Get Citation

Connect on Social Media

Connect on Social Media

Validation of the Polish version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

Joanna Siuda1, Magdalena Boczarska-Jedynak2, Sławomir Budrewicz3, Jarosław Dulski45, Monika Figura6, Urszula Fiszer7, Agata Gajos8, Agnieszka Gorzkowska9, Ewa Koziorowska-Gawron3, Dariusz Koziorowski6, Anna Krygowska-Wajs10, Monika Rudzińska-Bar11, Jarosław Sławek45, Xuehan Ren12, Sheng Luo13, Pablo Martinez-Martin14, Glenn Stebbins15, Christopher G. Goetz15, Grzegorz Opala1, MDS-UPDRS Polish Validation Task Force
Pubmed: 32639019
Neurol Neurochir Pol 2020;54(5):416-425.

Abstract

Introduction. In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson’s Disease (PD). We have translated and validated the Polish version of the MDS-UPDRS, explored its dimensionality, and compared it to the original English one. Methods. The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO. The back-translation was completed by colleagues fluent in both languages (Polish and English) who were not involved in the original translation, and was reviewed by members of the MDS Rating Scales Programme. Then the translated version of the MDS-UPDRS underwent cognitive pretesting, and the translation was modified based on the results. The final translation was approved as the Official Working Document of the MDS-UPDRS Polish version, and was tested on 355 Polish PD patients recruited at movement disorders centres all over Poland (at Katowice, Gdańsk, Łódź, Warsaw, Wrocław, and Kraków). Confirmatory and explanatory factor analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version. Results. The Polish version of the MDS-UPDRS showed satisfactory clinimetric properties. The internal consistency of the Polish version was satisfactory. In the confirmatory factor analysis, all four parts had greater than 0.90 comparative fit index (CFI) compared to the original English MDS-UPDRS. Explanatory factor analysis suggested that the Polish version differed from the English version only within an acceptable range. Conclusions and clinical implications. The Polish version of the MDS-UPDRS meets the requirements to be designated as the Official Polish Version of the MDS-UPDRS, and is available on the MDS web page. We strongly recommend using the MDS-UPDRS instead of the UPDRS for research purposes and in everyday clinical practice.

 

Article available in PDF format

View PDF Download PDF file

References

  1. Emamzadeh FN, Surguchov A. Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. Front Neurosci. 2018; 12: 612.
  2. Barc K, Kuźma-Kozakiewicz M. Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2019; 53(2): 99–112.
  3. Malec-Litwinowicz M, Plewka A, Plewka D, et al. The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease. Neurol Neurochir Pol. 2018; 52(2): 243–251.
  4. Fahn S, Elton RL, Members of, et al. Members of the UPDRS Develoment Committee. Unified Parkinson’s Disease rating scale. In:, , , , editors. Recent develoments in Parkinson’s disease, vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. : 153–164.
  5. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15): 2129–2170.
  6. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013; 260(1): 228–236.
  7. Goetz CG, Stebbins GT, Wang Lu, et al. IPMDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS. Mov Disord Clin Pract. 2014; 1(2): 97–101.
  8. Fowler FJ. Improving Survey Questions: Design and Evaluation. Applied Social Research Methods Series: 38. Thousand Oaks: Sage. : 1995.
  9. Muthen LK. and Muthen BO. M plus Version 7 User's Guide. Los Angeles, CA: Muthen. : Muthen.
  10. Hatcher L. Step-by-step approach to using the SAS system for factor analysis and structural equation modeling. 1994. SAS Inst. , Cary, NC. ; 73.
  11. Brown TA. Confirmatory factor analysis for applied research. New York: Guilford SAGE Publications, Inc. : 2006.
  12. Browne M. An Overview of Analytic Rotation in Exploratory Factor Analysis. Multivariate Behavioral Research. 2010; 36(1): 111–150.
  13. Gorsuch RL. Factor analysis. Second edition. Hillsdale, NJ: Lawrence Erlbaum Associations, Inc. : 1983.
  14. Gallagher DA, Goetz CG, Stebbins G, et al. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012; 27(1): 79–83.
  15. Goetz CG, Liu Y, Stebbins GT, et al. Gender-, age- and race/ethnicity-based Differential Item Functioning (DIF) analysis of MDS-UPDRS. Mov Disord. 2016; 31(12): 1865–1873.
  16. Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014; 21(3): 519–524.
  17. Balash Y, Korczyn AD, Knaani J, et al. Quality-of-life perception by Parkinson's disease patients and caregivers. Acta Neurol Scand. 2017; 136(2): 151–154.